Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
allitinib (AST1306) / Allist
NCT04671303: To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer	Not yet recruiting	2	36	NA	Anlotinib Hydrochloride Capsule Combined with Allitinib Tablets	Chinese Academy of Medical Sciences	Lung Cancer	09/21	09/21
ChiCTR-ONC-10000893: A Phase I Trial of Allitinib	Completed	1	70		Allitinib 400mg, 800mg, 1200mg, 1600mg, 2000mg or 2400mg, orally taken once daily or twice daily consecutively until meeting the withdrawal criteria	Fudan University Shanghai Cancer Center; Shanghai Allist Pharmaceuticals, Inc., Shanghai Allist Pharmaceuticals, Inc.	Advanced solid tumor